Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review
Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5-year survival rate for stage IV CRC patients. Conventional treatments fo...
| الحاوية / القاعدة: | International Journal of Pharmaceutics |
|---|---|
| المؤلف الرئيسي: | |
| التنسيق: | Review |
| اللغة: | English |
| منشور في: |
Elsevier B.V.
2024
|
| الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181882337&doi=10.1016%2fj.ijpharm.2023.123735&partnerID=40&md5=a6c0fe8ff883fc14b62d5c95d8a58466 |
| id |
Shazleen Ibrahim I.; Starlin Chellathurai M.; Mahmood S.; Hakim Azmi A.; Harun N.; Ulul Ilmie Ahmad Nazri M.; Muzamir Mahat M.; Mohamed Sofian Z. |
|---|---|
| spelling |
Shazleen Ibrahim I.; Starlin Chellathurai M.; Mahmood S.; Hakim Azmi A.; Harun N.; Ulul Ilmie Ahmad Nazri M.; Muzamir Mahat M.; Mohamed Sofian Z. 2-s2.0-85181882337 Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review 2024 International Journal of Pharmaceutics 651 10.1016/j.ijpharm.2023.123735 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181882337&doi=10.1016%2fj.ijpharm.2023.123735&partnerID=40&md5=a6c0fe8ff883fc14b62d5c95d8a58466 Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5-year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off-target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC. © 2023 Elsevier B.V. Elsevier B.V. 3785173 English Review |
| author |
2-s2.0-85181882337 |
| spellingShingle |
2-s2.0-85181882337 Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
| author_facet |
2-s2.0-85181882337 |
| author_sort |
2-s2.0-85181882337 |
| title |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
| title_short |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
| title_full |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
| title_fullStr |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
| title_full_unstemmed |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
| title_sort |
Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review |
| publishDate |
2024 |
| container_title |
International Journal of Pharmaceutics |
| container_volume |
651 |
| container_issue |
|
| doi_str_mv |
10.1016/j.ijpharm.2023.123735 |
| url |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181882337&doi=10.1016%2fj.ijpharm.2023.123735&partnerID=40&md5=a6c0fe8ff883fc14b62d5c95d8a58466 |
| description |
Colorectal cancer (CRC) continues to be one of the most prevalent and deadliest forms of cancer worldwide, despite notable advancements in its management. The prognosis for metastatic CRC remains discouraging, with a relative 5-year survival rate for stage IV CRC patients. Conventional treatments for advanced malignancies such as chemotherapy, often face limitations in effectively targeting cancer cells resulting in off-target distribution and significant side effects. In the quest for better strategies, researchers have explored numerous alternatives. Among these, nanoparticles (NPs) specifically liposomes have emerged as one of the most promising candidates in developing targeted delivery systems for cancer therapeutics. This review discusses the current approaches employing functionalised liposomes to overcome major biological barriers in therapeutics delivery for CRC treatment. We have also shared our perspectives on the technological development of liposomes for future clinical use and highlighted a few useful insights on the material choices for future research work in CRC. © 2023 Elsevier B.V. |
| publisher |
Elsevier B.V. |
| issn |
3785173 |
| language |
English |
| format |
Review |
| accesstype |
|
| record_format |
scopus |
| collection |
Scopus |
| _version_ |
1828987860855816192 |